Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2023-12-10
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees
NCT06536933
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
NCT05966025
The Effects of Dihydromiricetin on MASLD
NCT05052515
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD
NCT07194863
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
NCT06934642
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo group (conventional treatment + placebo tablet)
placebo tablet (inert substance) + Weight reduction and life style modification(modification in diet like decrease lipids intak).pateints will recieve their conventional therapy
Conventional therapy
conventional therapy
Placebo
placebo tablet (inert substance has the same shape and color of intervention) to be taken by control group only
intervention group: drug trimetazidine
trimetazidine 20 mg three times Aday plus lifestyle modification
Trimetazidine
trimetazidine at dose 20 mg three times daily to be taken by intervention group
Conventional therapy
conventional therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trimetazidine
trimetazidine at dose 20 mg three times daily to be taken by intervention group
Conventional therapy
conventional therapy
Placebo
placebo tablet (inert substance has the same shape and color of intervention) to be taken by control group only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* drug-induced injury, hepatitis C, Wilson disease).
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
October 6 University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maha youssif
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hoda m rabea, Assistant Professor
Role: PRINCIPAL_INVESTIGATOR
Beni-suaf university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beni-Suef university
Banī Suwayf, Beni Suweif Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REC-H-phBSU-23059
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.